Which is better, IRMD or LMAT?

On the Buffett-Fit framework, IRadimed Corporation (IRMD) currently grades higher than LMAT — 68/100 (B grade) vs 77/100 (B). That said, "better" depends on which framework you trust — IRMD wins on Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith; LMAT wins on Warren Buffett. The full pillar breakdown is on this page.

Should I buy IRMD or LMAT?

This page is an educational comparison, not investment advice. Both IRMD and LMAT are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is IRMD better than LMAT for value investing?

On the Buffett-style value-investing framework, IRMD currently grades higher — 77/100 vs 68/100, a 9-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between IRMD and LMAT on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). IRMD currently scores 68/100 (B grade); LMAT scores 77/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, IRMD or LMAT?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. IRMD and LMAT are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, IRMD or LMAT?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are IRMD and LMAT both Healthcare stocks?

Yes — both IRadimed Corporation (IRMD) and LeMaitre Vascular, Inc. (LMAT) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this IRMD vs LMAT comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

IRadimed

LeMaitre Vascular

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

IRMD

IRadimed

Market cap

$1.18B

Sector

Healthcare

LMAT

LeMaitre Vascular

Market cap

$2.23B

Sector

Healthcare

Overall winner

IRadimed IRMD

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	IRMD	LMAT	Winner
Warren Buffett	68B	77B	LMAT
Benjamin Graham	89A	89A	Tie
Philip Fisher	92A	81C	IRMD
Peter Lynch	76B	67B	IRMD
Joel Greenblatt	65C	56D	IRMD
Charlie Munger	78B	68D	IRMD
Terry Smith	75B	69D	IRMD

Side-by-side metrics

Metric	IRMD	LMAT
Market cap	$1.18B	$2.23B
P/E (TTM)	50.4x	37.1x
EV/EBIT	43.4x	36.6x
ROIC (TTM)	21.38%	9.43%
Gross margin	76.84%	72.39%
Net margin	27.36%	24.35%
Revenue CAGR 5y	18.99%	12.75%
EPS CAGR 5y	23.53%	19.04%
Debt / Equity	-	0.5x
Dividend yield	1.33%	0.84%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

IRMD leads on

Debt / Equity-vs 0.5x+100%
ROIC (TTM)21.38%vs 9.43%+56%
Dividend yield1.33%vs 0.84%+37%
Revenue CAGR 5y18.99%vs 12.75%+33%

LMAT leads on

Market cap$2.23Bvs $1.18B+47%
P/E (TTM)37.1xvs 50.4x+26%
EV/EBIT36.6xvs 43.4x+16%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

IRadimed

LeMaitre Vascular

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like IRMD

More like LMAT

Related on invest-like

Key terms in this analysis